Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant Therapy for Oral Cancer Mandible Preservation
NCT06130007Phase 2Unknown
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in oral squamous cell carcinoma (OSCC). Primary endpoint: Mandibular Preservation Rate at 12 weeks. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06130007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130007.